Customize
Quick Links
Past Events

Accreditation/
Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 22.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 22.0 Contact Hours.


Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for a maximum of 22.0 contact hours (0.22 CEUs).

Acknowledgment of Commercial Support

This activity is supported by educational grants from Ariad Pharmaceuticals, Inc., Astellas, AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Exelixis, Inc., Genomic Health, Inc., Incyte, Lilly, Medivation, Inc., Merck, NantHealth, Inc., Novartis Pharmaceuticals Corporation, Novocure Inc., Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Sirtex, Taiho Oncology, Inc., Takeda Oncology, Tesaro, Inc., and Teva Pharmaceuticals.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.



The CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is wholly owned and operated by PER Events, LLC, an affiliate of Physicians' Education Resource®.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

34th Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

34th Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®


Atul Butte, MD, PhD

Join us on Friday, November 11 at 11:25am, to hear Dr. Atul Butte’s presentation "Translating a Trillion Points of Data into Therapies, Diagnostics, and New Insights into Disease."


Atul Butte, MD, PhD Atul Butte, MD, PhD, is the inaugural Director of the Institute of Computational Health Sciences (ICHS) and a Distinguished Professor of Pediatrics at the University of California, San Francisco.  Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers.  Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children's Hospital Boston, then received his PhD from Harvard Medical School and MIT.

Dr. Butte has authored nearly 200 publications, with research repeatedly featured in Wired Magazine, the New York Times, and the Wall Street Journal.  In 2015, Dr. Butte was elected into the National Academy of Medicine (formally known as the Institute of Medicine). In 2013, Dr. Butte was recognized by the White House as an Open Science Champion of Change for promoting science through publicly available data.  


Other recent awards include

  • The 2014 E. Mead Johnson Award for Research in Pediatrics
  • 2013 induction into the American Society for Clinical Investigation
  • The 2011 National Human Genome Research Institute Genomic Advance of the Month
  •  

Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis, providing clinical interpretation of whole genome sequences, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte is also the principal investigator of the California Initiative to Advance Precision Medicine, and the principal investigator for ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases.







Become a Member

Forgot Password?
Filter By